CM-AT Protein Digestion in Autism Clinical Trial Study

Call for Participants
CM-AT Protein Digestion in Autism Clinical Trial Study

The MEND Clinic at Vanderbilt is now enrolling patients in Phase III clinical trials for CM-AT, a treatment for autism. CM-AT is developed by Curemark LLC, a drug research and development company focused on the treatment of neurological diseases. CM-AT is based on Curemark’s recent research that showed enzyme deficiencies in some autistic children result in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. Vanderbilt is one of 25 sites across the country conducting the CM-AT clinical trials. For information on participating in the trial, contact Sarah Marler at (615) 936-3288 or sarah.marler@vanderbilt.edu.

Comments

    john f | December 13, 2016 at 2:57 pm

    I would like to read any responses to this study

Write a Comment

Your email address will not be published. Required fields are marked *